C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Monday, down -4.25% from the previous trading day, before settling in for the closing price of $2.12. Over the past 52 weeks, CCCC has traded in a range of $1.09-$4.26.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -8.92%. While this was happening, its average annual earnings per share was recorded 7.51%. With a float of $78.37 million, this company’s outstanding shares have now reached $96.91 million.
C4 Therapeutics Inc (CCCC) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 19.13%, while institutional ownership is 57.44%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.49 earnings per share (EPS), lower than consensus estimate (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.69% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Compared to the last year’s volume of 1.61 million, its volume of 1.07 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 25.09%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 5.81%, which indicates a significant decrease from 13.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.13 in the past 14 days, which was lower than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $2.08. Nevertheless, the first resistance level for the watch stands at $2.10 in the near term. At $2.18, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.22. If the price goes on to break the first support level at $1.99, it is likely to go to the next support level at $1.95. Should the price break the second support level, the third support level stands at $1.87.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
The company with the Market Capitalisation of 196.74 million has total of 96,914K Shares Outstanding. Its annual sales at the moment are 35,580 K in contrast with the sum of -105,320 K annual income. Company’s last quarter sales were recorded 11,230 K and last quarter income was -32,170 K.
